Capricor Granted Orphan Drug Designation For CAP-1002 CDCs - Quick Facts

(RTTNews) - Capricor Therapeutics, Inc. (CAPR) announced it has been granted orphan drug designation by the U.S. FDA for its cell therapeutic product candidate, CAP-1002, for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. Cardiosphere-derived cells, CDCs, also known as CAP-1002, are a potential therapeutic approach for the treatment of Duchenne muscular dystrophy-associated cardiomyopathy.

Linda Marbán, CEO of Capricor, said: "We anticipate filing an IND with the FDA in the near future and hope to be treating patients with Duchenne later this year subject to regulatory approval. We look forward to reporting additional milestones as they are achieved."